For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward

Proper randomisation means little if investigators cannot include all randomised participants in the primary analysis. Participants might ignore follow-up, leave town, or take aspartame when instructed to take aspirin. Exclusions before randomisation do not bias the treatment comparison, but they can hurt generalisability. Eligibility criteria for a trial should be clear, specific, and applied before randomisation. Readers should assess whether any of the criteria make the trial sample atypical or unrepresentative of the people in which they are interested. In principle, assessment of exclusions after randomisation is simple: none are allowed. For the primary analysis, all participants enrolled should be included and analysed as part of the original group assigned (an intent-to-treat analysis). In reality, however, losses frequently occur. Investigators should, therefore, commit adequate resources to develop and implement procedures to maximise retention of participants. Moreover, researchers should provide clear, explicit information on the progress of all randomised participants through the trial by use of, for instance, a trial profile. Investigators can also do secondary analyses on, for instance, per-protocol or as-treated participants. Such analyses should be described as secondary and non-randomised comparisons. Mishandling of exclusions causes serious methodological difficulties. Unfortunately, some explanations for mishandling exclusions intuitively appeal to readers, disguising the seriousness of the issues. Creative mismanagement of exclusions can undermine trial validity.

[1]  Mark C. Wilson Evidence-Based Medicine: How to Practice and Teach EBM , 2001, ACP Journal Club.

[2]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[3]  Kenneth F Schulz,et al.  Allocation concealment in randomised trials: defending against deciphering , 2002, The Lancet.

[4]  S. Satya‐Murti Evidence-based Medicine: How to Practice and Teach EBM , 1997 .

[5]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[6]  J H Ellenberg,et al.  Analysis of clinical trials by treatment actually received: is it really an option? , 1991, Statistics in medicine.

[7]  U. Tamoufé,et al.  Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. , 2002, JAMA.

[8]  C. Meinert,et al.  Content of reports on clinical trials: a critical review. , 1984, Controlled clinical trials.

[9]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[10]  D. Machin,et al.  Intention to treat--who should use ITT? , 1993, British Journal of Cancer.

[11]  Frederick Mosteller,et al.  Reporting on methods in clinical trials. , 1982, The New England journal of medicine.

[12]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[13]  P. Meier Anturane reinfarction trial. , 1981, New England Journal of Medicine.

[14]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[15]  K. Schulz,et al.  An overview of clinical research: the lay of the land , 2002, The Lancet.

[16]  C. Bulpitt,et al.  Clinical Trials—Issues and Approaches , 1984 .

[17]  R. J. Hayes,et al.  Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology , 1996, BMJ.

[18]  Sulfinpyrazone in the prevention of sudden death after myocardial infarction. , 1980, The New England journal of medicine.

[19]  J M Lachin,et al.  Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.

[20]  G. Pledger,et al.  The FDA's critique of the anturane reinfarction trial. , 1980, The New England journal of medicine.

[21]  Kenneth F Schulz,et al.  Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.

[22]  T. Louis,et al.  Clinical trials : issues and approaches , 1984 .